Brown Simon D, Klimi Eftychia, Bakker Wilfried A M, Beqqali Abdelaziz, Baker Andrew H
BHF Centre for Cardiovascular Science, Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK.
Batavia Biosciences B.V., Bioscience Park Leiden, Leiden, The Netherlands.
Br J Pharmacol. 2025 Jan;182(2):246-280. doi: 10.1111/bph.16409. Epub 2024 May 21.
Vascular smooth muscle cell (vSMC) dysfunction is a critical contributor to cardiovascular diseases, including atherosclerosis, restenosis and vein graft failure. Recent advances have unveiled a fascinating range of non-coding RNAs (ncRNAs) that play a pivotal role in regulating vSMC function. This review aims to provide an in-depth analysis of the mechanisms underlying vSMC dysfunction and the therapeutic potential of various ncRNAs in mitigating this dysfunction, either preventing or reversing it. We explore the intricate interplay of microRNAs, long-non-coding RNAs and circular RNAs, shedding light on their roles in regulating key signalling pathways associated with vSMC dysfunction. We also discuss the prospects and challenges associated with developing ncRNA-based therapies for this prevalent type of cardiovascular pathology. LINKED ARTICLES: This article is part of a themed issue Non-coding RNA Therapeutics. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.2/issuetoc.
血管平滑肌细胞（vSMC）功能障碍是心血管疾病的关键促成因素，这些疾病包括动脉粥样硬化、再狭窄和静脉移植物衰竭。最近的进展揭示了一系列引人入胜的非编码RNA（ncRNA），它们在调节vSMC功能中起着关键作用。本综述旨在深入分析vSMC功能障碍的潜在机制，以及各种ncRNA在减轻这种功能障碍（预防或逆转）方面的治疗潜力。我们探讨了微小RNA、长链非编码RNA和环状RNA之间复杂的相互作用，阐明了它们在调节与vSMC功能障碍相关的关键信号通路中的作用。我们还讨论了针对这种常见心血管病理开发基于ncRNA疗法的前景和挑战。相关文章：本文是主题为“非编码RNA疗法”的一部分。要查看本节中的其他文章，请访问http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.2/issuetoc。
